Digitalis
Digitalis is an unknown pharmaceutical. It is currently being investigated in clinical studies.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
No data
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
C: Cardiovascular system drugs
— C01: Cardiac therapy drugs
— C01A: Cardiac glycosides
— C01AA: Digitalis glycosides
— C01AA03: Digitalis leaves
V: Various drug classes in atc
— V03: All other therapeutic products
— V03A: All other therapeutic products
— V03AB: Antidotes
— V03AB24: Digitalis antitoxin
HCPCS
No data
Clinical
Clinical Trials
207 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 69 | — | — | 1 | — | 70 |
| Atrial fibrillation | D001281 | EFO_0000275 | I48.0 | 1 | — | 5 | 3 | 8 | 17 |
| Heart failure | D006333 | EFO_0003144 | I50 | 1 | 1 | 3 | 7 | 3 | 15 |
| Drug-related side effects and adverse reactions | D064420 | — | T88.7 | — | — | — | 1 | — | 1 |
| Cardio-renal syndrome | D059347 | — | — | — | — | — | 1 | — | 1 |
| Pathologic dilatation | D004108 | — | — | — | — | — | 1 | — | 1 |
| Renal insufficiency | D051437 | — | N19 | — | — | — | 1 | — | 1 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Heart diseases | D006331 | EFO_0003777 | I51.9 | — | — | 3 | — | 2 | 5 |
| Tachycardia | D013610 | — | R00.0 | 1 | — | 2 | — | 1 | 4 |
| Supraventricular tachycardia | D013617 | — | I47.1 | — | — | 2 | — | 1 | 3 |
| Cardiac arrhythmias | D001145 | EFO_0004269 | I49.9 | — | — | 2 | — | 1 | 3 |
| Cardiovascular diseases | D002318 | EFO_0000319 | I98 | — | — | 2 | — | — | 2 |
| Atrial flutter | D001282 | EFO_0003911 | — | — | — | 1 | — | — | 1 |
| Edema | D004487 | — | R60.9 | — | — | 1 | — | — | 1 |
| Sinus arrhythmia | D001146 | — | — | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Type 2 diabetes mellitus | D003924 | EFO_0001360 | E11 | 8 | 1 | — | — | — | 9 |
| Breast neoplasms | D001943 | EFO_0003869 | C50 | 2 | 2 | — | — | 1 | 5 |
| Rheumatoid arthritis | D001172 | EFO_0000685 | M06.9 | 4 | 1 | — | — | — | 5 |
| Arthritis | D001168 | EFO_0005856 | M05-M14 | 4 | 1 | — | — | — | 5 |
| Diabetes mellitus | D003920 | EFO_0000400 | E08-E13 | 4 | 1 | — | — | — | 5 |
| Fatty liver | D005234 | EFO_0003934 | — | 1 | 3 | — | — | — | 4 |
| Non-small-cell lung carcinoma | D002289 | — | — | 2 | 1 | — | — | — | 3 |
| Pancreatic neoplasms | D010190 | EFO_0003860 | C25 | 2 | 2 | — | — | — | 3 |
| Fibrosis | D005355 | — | — | — | 2 | — | — | 1 | 3 |
| Non-alcoholic fatty liver disease | D065626 | EFO_0003095 | K75.81 | 1 | 2 | — | — | — | 3 |
Show 29 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Neoplasms | D009369 | — | C80 | 12 | — | — | — | — | 12 |
| Drug interactions | D004347 | — | — | 8 | — | — | — | — | 8 |
| Overweight | D050177 | — | E66.3 | 5 | — | — | — | — | 5 |
| Melanoma | D008545 | — | — | 3 | — | — | — | — | 3 |
| Pharmacokinetics | D010599 | — | — | 3 | — | — | — | — | 3 |
| Tuberculosis | D014376 | EFO_0000774 | A15-A19 | 2 | — | — | — | — | 2 |
| Hiv infections | D015658 | EFO_0000764 | B20 | 2 | — | — | — | — | 2 |
| Epilepsy | D004827 | EFO_0000474 | G40.9 | 2 | — | — | — | — | 2 |
| Hereditary angioedemas | D054179 | EFO_0004131 | — | 1 | — | — | — | — | 1 |
| Angioedema | D000799 | EFO_0005532 | T78.3 | 1 | — | — | — | — | 1 |
Show 34 more
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Induced abortion | D000028 | — | — | — | — | — | — | 2 | 2 |
| Congenital heart defects | D006330 | — | Q24.9 | — | — | — | — | 1 | 1 |
| Exercise test | D005080 | EFO_0004328 | — | — | — | — | — | 1 | 1 |
| Hypertension | D006973 | EFO_0000537 | I10 | — | — | — | — | 1 | 1 |
| Pulmonary hypertension | D006976 | EFO_0001361 | I27.20 | — | — | — | — | 1 | 1 |
| Bipolar disorder | D001714 | EFO_0000289 | F30.9 | — | — | — | — | 1 | 1 |
| Mammaplasty | D016462 | — | — | — | — | — | — | 1 | 1 |
| Breast diseases | D001941 | — | N60-N65 | — | — | — | — | 1 | 1 |
| Fibrocystic breast disease | D005348 | — | N60 | — | — | — | — | 1 | 1 |
| Carcinoma | D002277 | — | C80.0 | — | — | — | — | 1 | 1 |
Show 4 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Digitalis |
| INN | _ |
| Description | Digitoxin is a cardenolide glycoside in which the 3beta-hydroxy group of digitoxigenin carries a 2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1->4)-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1->4)-2,6-dideoxy-beta-D-ribo-hexopyranosyl trisaccharide chain. It has a role as an EC 3.6.3.9 (Na(+)/K(+)-transporting ATPase) inhibitor. It is functionally related to a digitoxigenin. It is a conjugate acid of a digitoxin(1-). |
| Classification | Unknown |
| Drug class | — |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | — |
Identifiers
| PDB | — |
| CAS-ID | — |
| RxCUI | — |
| ChEMBL ID | CHEMBL2109172 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | — |
| UNII ID | UD4O8TY7RW (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
No data
Trends
No data
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
58 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use